摘要
目的探讨过敏性鼻炎（AR）患者血清IL-17和IL-22水平的变化及其与病情严重程度的关系。方法随机选取2012-01～2013-12间在我院收治的中重度AR患者122例作为观察组,另选取30例同期健康同龄查体者作为对照。采用ELISA法检测两组血清IL-17和IL-22水平。观察组均接受相应的治疗并于治疗10周后、治疗20周后、治疗40周后和治疗1年时复查以上项目。同时统计治疗前后患者过敏性鼻炎症状评分（SFAR）和伴随症状的视觉模拟量表（VAS）,分析不同SFAR和VAS得分患者的血清IL-17和IL-22水平,并采用Pearson相关性分析法分析患者血清IL-17和IL-22水平与其SFAR及VAS的关系。结果与对照组比较,观察组治疗前后血清IL-17和IL-22水平均升高;与治疗前比较,观察组治疗20周后、治疗40周和治疗1年后血清IL-17和IL-22水平均降低,差异有统计学意义（P〈0.05）。观察组治疗前SFAR分值为（9.58±2.05）分,高于治疗20周后、治疗40周后和治疗1年后的（6.16±1.49）分、（4.26±1.13）分和（2.21±0.85）分;观察组治疗20周后、治疗40周后和治疗1年时的VAS得分亦低于治疗前,差异有统计学意义（P〈0.05）。观察组治疗前SFAR0～2分、3～4分、5分以上的患者比例分别为9.02%、18.85%和72.13%,其中SFAR 3～4分、5分以上患者血清IL-17和IL-22水平均高于于0～2分患者,SFAR 5分以上患者血清IL-17和IL-22水平亦高于3～4分患者;且VAS得分较高患者血清IL-17和IL-22水平亦较高（P〈0.05）。Pearson相关性分析结果显示,血清IL-17和IL-22水平与AR患者SFAR和VAS均呈正相关（SFAR：r=0.792,0.798;VAS：r=0.783,0.789,P〈0.05）。结论 AR患者血清IL-17和IL-22水平较高且与其症状和伴随症状严重程度相关,这可能与IL-17和IL-22的促炎作用促进过敏反应发展相关,血清IL-17和IL-22可能作为AR患者病情严重程度评价的参考指标。
Objective To study the serum IL- 17 and IL- 22 level changes in allergic rhinitis（ AR） patients and its relationship with disease severity. Methods 122 AR patients in the hospital from January,2012 to December,2013 were randomly selected as observation group,and 30 healthy patients having physical examination in the hospital in the same period were selected as control group. ELISA method was used to detect serum IL- 17 and IL- 22 level of the two groups. Observation group were treated accordingly and the objects above were detected after treated for 10 weeks,20 weeks,40 weeks and 1 year. Allergic nose pharynx symptom scores（ SFAR） and the accompanying symptoms of visual analog scale（ VAS） of observation group before and after treatment were statistically analyzed,serum IL- 17 and IL-22 level of patients with different SFAR and VAS score were compared,and correlation analysis was used in analyzing relationship between serum IL- 17,IL- 22 level and SFAR,VAS score. Results Compared with control group,serum IL- 17 and IL- 22 level of observation group before and after treatment was higher; Compared with before treatment,serum IL- 17 and IL- 22 level of observation group after 20 weeks,40 weeks and 1 year treatment were lower; And the difference was statistically significant（ P〈0. 05）. SFAR score of observation group before treatment was（ 9. 58 ± 2. 05）,which was higher than（ 6. 16 ± 1. 49）,（ 4. 26 ± 1. 13） and（ 2. 21 ± 0. 85） points of after 20 weeks,40 weeks and 1 year treatment; VAS score of observation group after 20 weeks,40 weeks and 1 year treatment were lower than before the treatment,and the difference was statistically significant（ P〈0. 05）. Patients rate with SFAR as 0 ～ 2 points,3 ～ 4 points,above5 points in observation group before treatment were 9. 02%,18. 85% and 72. 13% respectively; And serum IL- 17 and IL- 22 level of patients with SFAR as 3 ～ 4 points and above 5 points were higher than those of patients with SFAR as 0 ～ 2 points; SFAR5 serum IL- 17 and IL- 22 level of patients with SFAR as 5 points were higher than those of patients with SFAR as 3 ～ 4 points; And patients having VAS score also had higher serum IL- 17 and IL- 22 level（ P〈0. 05）. Pearson correlation analysis results showed that the level of serum IL- 17 and IL- 22 level of AR patients were positively correlated with SFAR and VAS（ SFAR： r = 0. 792,0. 798; VAS： r = 0. 783,0. 789,P〈0. 05）. Conclusion Serum IL- 17 and IL- 22 level of AR patients are high and associated with symptom severity,it may be related to IL- 17 and IL- 22 promoting inflammatory so as to improve allergic reaction role,thus serum IL- 17 and IL- 22 may be as a reference indicator in severity evaluation of AR patients.
出处
《黑龙江医学》
2015年第8期921-925,共5页
Heilongjiang Medical Journal
